Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03283371 |
|---|---|
| Brief Title: | Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy (OPUS) |
| First Submitted : | September 12, 2017 |
| First Submitted that Met QC Criteria : | September 12, 2017 |
| First Posted : | September 14, 2017 |
| Last Update Submitted that Met QC Criteria : | August 22, 2019 |
| Last Update Posted : | August 26, 2019 |